Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria
- PMID: 9012693
- DOI: 10.1046/j.1365-2141.1997.d01-1984.x
Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria
Abstract
Seven patients with paroxysmal nocturnal haemoglobinuria (PNH) were treated with antithymocyte globulin (ATG). Each patient received ATG (20 mg/kg/d) for 8 d and prednisone to prevent or control serum sickness. Three patients experienced a sustained improvement in at least one peripheral blood cytopenia, including one patient who had a complete trilineage response. Several pretreatment clinical features appeared to be associated with response to ATG. All responding patients had hypoproliferative features including depressed platelet counts (< 30 x 10(9)/l), and a minor degree of chronic haemolysis as indicated by relatively low reticulocyte counts (< 100 x 10(9)/l), lactate dehydrogenase (< 1000 U/l) and total bilirubin (< 17 mumol/l) levels. Responding patients continued to have chronic low-grade haemolysis after their response to immunosuppression that was similar to that observed prior to treatment. The non-responding patients had a classic haemolytic form of PNH characterized by elevated reticulocyte counts (> 100 x 10(9)/l), lactate dehydrogenase (> 2000 U/l) and total bilirubin (> 17 mumol/l) levels. The impaired haemopoiesis that occurs in hypoproliferative PNH may respond to ATG treatment, but the haemolytic component of the disease, and hence the PNH clone, is not altered by immunosuppressive therapy.
Similar articles
-
Cell cycling stress in the monocyte line as a risk factor for progression of the aplastic anaemia/paroxysmal nocturnal haemoglobinuria syndrome to myelodysplastic syndrome.Acta Haematol. 2000;103(1):33-40. doi: 10.1159/000041002. Acta Haematol. 2000. PMID: 10705157
-
[Immunosuppressive therapy with antithymocyte globulin and cyclosporine for paroxysmal nocturnal hemoglobinuria].Rinsho Ketsueki. 2008 Jul;49(7):498-504. Rinsho Ketsueki. 2008. PMID: 18709982 Japanese.
-
Apparent hemolysis following intravenous antithymocyte globulin treatment in a patient with marrow failure and a paroxysmal nocturnal hemoglobinuria clone.Transfusion. 2006 Jul;46(7):1244-7. doi: 10.1111/j.1537-2995.2006.00877.x. Transfusion. 2006. PMID: 16836574
-
[Clinical profile and course of paroxysmal nocturnal hemoglobinuria].Sangre (Barc). 1993 Aug;38(4):301-7. Sangre (Barc). 1993. PMID: 8235945 Review. Spanish.
-
Clonal evolution of aplastic anaemia to myelodysplasia/acute myeloid leukaemia and paroxysmal nocturnal haemoglobinuria.Leuk Lymphoma. 1999 Apr;33(3-4):231-41. doi: 10.3109/10428199909058423. Leuk Lymphoma. 1999. PMID: 10221503 Review.
Cited by
-
Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment.Medicina (Kaunas). 2023 Sep 6;59(9):1612. doi: 10.3390/medicina59091612. Medicina (Kaunas). 2023. PMID: 37763731 Free PMC article. Review.
-
Paroxysmal nocturnal hemoglobinuria in childhood and adolescence--a retrospective analysis of 18 cases.Indian J Pediatr. 2008 Jun;75(6):575-8. doi: 10.1007/s12098-008-0111-9. Epub 2008 Aug 31. Indian J Pediatr. 2008. PMID: 18759084
-
New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.Int J Hematol. 2007 Jul;86(1):27-32. doi: 10.1532/IJH97.07029. Int J Hematol. 2007. PMID: 17675263 Review.
-
The status of antithymocyte globulin therapy for adult patients in Japan: retrospective analysis of a nationwide survey.Int J Hematol. 2008 Jan;87(1):48-55. doi: 10.1007/s12185-007-0016-9. Epub 2007 Dec 8. Int J Hematol. 2008. PMID: 18224413
-
Neutral evolution in paroxysmal nocturnal hemoglobinuria.Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18496-500. doi: 10.1073/pnas.0802749105. Epub 2008 Nov 14. Proc Natl Acad Sci U S A. 2008. PMID: 19011109 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources